Xia LZ, Liu Y, Xu XZ, Jiang PC, Ma G, Bu XF, Zhang YJ, Yu F, Xu KS, Li H. Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer susceptibility. World J Gastroenterol 2014; 20(32): 11429-11438 [PMID: 25170232 DOI: 10.3748/wjg.v20.i32.11429]
Corresponding Author of This Article
Hua Li, MD, Department of General Surgery, Affiliated People’s Hospital, Jiangsu University, No. 8, Dianli Road, Zhenjiang 212002, Jiangsu Province, China. drlihua212@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Lei-Zhou Xia, Peng-Cheng Jiang, Gui Ma, Xue-Feng Bu, Yong-Jun Zhang, Feng Yu, Hua Li, Department of General Surgery, Affiliated People’s Hospital, Jiangsu University, Zhenjiang 212002, Jiangsu Province, China
Yi Liu, Ke-Sen Xu, Department of Hepatobiliary Surgery, Qilu Hospital, Shandong University, Jinan 250012, Shandong Province, China
Xiao-Zhou Xu, Department of Surgery, Chang-Hai Hospital, The Second Military Medical University, Shanghai 200000, China
ORCID number: $[AuthorORCIDs]
Author contributions: Xia LZ and Li H designed the research; Xia LZ, Liu Y, Xu XZ, Jiang PC, Ma G, Bu XF, Zhang YJ, Yu F and Xu KS performed the data search and meta-analysis; Xia LZ wrote the paper.
Correspondence to: Hua Li, MD, Department of General Surgery, Affiliated People’s Hospital, Jiangsu University, No. 8, Dianli Road, Zhenjiang 212002, Jiangsu Province, China. drlihua212@163.com
Telephone: +86-511-88915151 Fax: +86-511-88915151
Received: October 8, 2013 Revised: March 4, 2014 Accepted: May 12, 2014 Published online: August 28, 2014 Processing time: 324 Days and 14 Hours
Abstract
AIM: To identify the association between methylenetetrahydrofolate reductase (MTHFR) polymorphisms and gastric cancer (GC) susceptibility.
METHODS: Systematic searches were performed on the electronic databases PubMed, ISI, Web of knowledge, CNKI and Wanfang, as well as manual searching of the references of the identified articles. A total of 26 papers were included in this meta-analysis. Overall and subgroup analyses were performed. Odds ratio (OR) and 95%CI were used to evaluate the associations between MTHFR polymorphisms and GC risk. The I2 statistics were used to evaluate between-study heterogeneity. Sensitivity analysis was also performed.
RESULTS: Increased risk was found for the MTHFR C677T polymorphism under four genetic models (TT + CT vs CC: OR = 1.23, P = 0.002; T vs C: OR = 1.15, P = 0.001; TT vs CC: OR = 1.37, P = 0.0005; TT vs CT + CC: OR = 1.17, P = 0.0008). Subgroup analysis by ethnicity suggested that C677T polymorphism conferred a risk of GC in eastern but not in western populations. Stratification by tumor site showed an association between the C677T polymorphism and gastric cardia cancer and non-cardia GC in the worldwide population and in eastern populations. Regardless of comparisons with controls or diffuse-type GC, a positive association was found for the C677T polymorphism and an increased risk of intestinal-type GC in the whole population and in western populations. With regard to the A1298C polymorphism, we found that genotype CC was significantly decreased and conferred protection against GC in eastern populations (CC vs AA: OR = 0.44, P = 0.03; CC vs AC + AA: OR = 0.46, P = 0.04).
CONCLUSION: MTHFR C677T polymorphism is a risk factor for GC, and the A1298C polymorphism may be a protective factor against GC in eastern populations.
Core tip: Many studies have reported associations of methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms with susceptibility to gastric cancer (GC). There are several relevant published meta-analyses about this subject. Nevertheless, these articles failed to analysis MTHFR polymorphisms and GC risk per se in detail as follows. They failed to investigate the difference between gastric cardia cancer and non-cardia GC, and the distinction between diffuse and intestinal subtypes. Consequently, we performed a meta-analysis to clarify the roles of MTHFR C677T and A1298C polymorphisms in GC susceptibility among the eligible studies.
Citation: Xia LZ, Liu Y, Xu XZ, Jiang PC, Ma G, Bu XF, Zhang YJ, Yu F, Xu KS, Li H. Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer susceptibility. World J Gastroenterol 2014; 20(32): 11429-11438
The incidence of gastric cancer (GC) has decreased worldwide, but it remains the fourth most common cancer diagnosis in men and the fifth in women[1], and the second leading cause of cancer-related death[2,3]. The etiology of GC is believed to be multi-stage and multifactorial. Although the decrease in the incidence of GC[4] in recent decades can be explained by changing lifestyles, diet habits, and reduced Helicobacter pylori infection, the fact that some individuals develop GC while others do not under similar environmental circumstances suggests that genetic predisposition plays an important role in the pathogenesis of GC.
Methylenetetrahydrofolate reductase (MTHFR), wh-ose gene maps to chromosome 1p36.3[5] and encodes a 77-kDa protein[6], plays a key role in folate metabolism by irreversibly catalyzing the reduction of 5, 10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the predominant circulatory form of folate, which serves as both a cofactor and substrate for the regeneration of methionine. The latter leads to production of S-adenosylmethionine (SAM); the universal methyl donor in humans for DNA methylation[7]. Reduced enzyme activity may result in lower levels of SAM and an increased risk of cancer, including GC, as a consequence of gene hypomethylation[8]. Two common single nucleotide polymorphisms (SNPs) of MTHFR have been indicated: C677T (rs1801133), which results in the amino acid product changing from alanine to valine[9]; and A1298C (rs1801131), which results in the amino acid product changing from glutamic acid to alanine[8]. Studies have confirmed that the variant genotypes are associated with a significant reduction of enzyme activity[10,11], suggesting that the polymorphisms of C677T and A1298C may be related to the risk of GC.
Until now, many studies have reported associations of MTHFR C677T and A1298C polymorphisms with susceptibility to GC with controversial results[12-37]. Additionally, there have been several relevant meta-analyses published on this subject[38-44]. Nevertheless, these studies failed to analyze MTHFR polymorphisms and GC risk per se in detail as follows. They failed to address the difference between gastric cardia cancer (GCC) and non-cardia gastric cancer (NCGC) as well as the distinction between diffuse and intestinal subtypes. Consequently, we performed a meta-analysis to clarify the roles of MTHFR C677T and A1298C polymorphisms in GC susceptibility among the eligible studies.
MATERIALS AND METHODS
Search strategy
Two researchers independently performed a computerized search in four databases - PubMed, ISI Web of Knowledge (Version 4.5), Chinese National Knowledge Infrastructure, and Wanfang (Chinese) - up to May 2013. Moreover, an additional search was carried out for relevant studies on scholar.google.com.hk. The search terms were ‘‘methylenetetrahydrofolate reductase’’ or MTHFR, “gastric or stomach or cardia” and “cancer or carcinoma or neoplasm” in various combinations, with the language limited to English and Chinese. The reference list of each relevant publication was also reviewed to ensure that all appropriate studies were included in the meta-analysis.
Inclusion and exclusion criteria
Studies were included according to the following criteria: (1) case-control or cohort studies determining the distribution of MTHFR C677T and/or A1298C genotypes; (2) cases with GC were diagnosed by histopathological biopsy, and the controls were free of cancer; and (3) the numbers of cases and controls reported for each genotype should be sufficient for calculation. If multiple studies from the same case series were available, the one including the most individuals was used in the analysis. We excluded the studies if they were: (1) meeting abstracts, case reports, reviews, or editorials; (2) not written in English or Chinese; or (3) not in Hardy-Weinberg equilibrium (HWE) with the controls. The final included studies were based on discussion among the researchers.
Data extraction
Two investigators independently extracted data from the published reports using a standardized protocol and a reporting form with the following information: first author’s last name, year of publication, country and ethnicity of participants (classified into eastern and western), sample size, detailed genotype information (genotype distribution and allele frequency), anatomical site of tumor (cardia or non-cardia GC) and Lauren classification (intestinal or diffuse subtype).
Statistical analysis
The MTHFR C677T genotypes include TT, CT and CC, and A1298C comprises CC, AC and AA genotypes. The pooled odds ratios (ORs) were calculated for the dominant model [C677T: (TT + CT) vs CC; A1298C: (CC + AC) vs AA], the allelic model (C677T: T allele vs C allele; A1298C: C allele vs A allele), the additive model (C677T: TT vs CC; A1298C: CC vs AA), and the recessive model (C677T: TT vs (CT + CC); A1298C: CC vs (AC + AA), respectively. Given that the potential causes of heterogeneity among studies were ethnicity, tumor site and classification, subgroup analyses were conducted according to different ethnic groups (Eastern/Western), tumor site (cardia/non-cardia), and Lauren classification (intestinal/diffuse).
RevMan software (Review Manager, Version 5.1; Cochrane Collaboration, 2011) was used for this meta-analysis. The between-study heterogeneity (i.e., the variation in findings not compatible with chance alone) was tested with the χ2-based Cochran’s statistic and the inconsistency index (I2). Statistically significant heterogeneity was considered to be present when Pheterogeneity < 0.05 and I² > 50%. If there was no statistical heterogeneity among studies (I2 < 50% and Pheterogeneity > 0.05), the OR and 95%CI were estimated for each study in a fixed-effects model (FEM). Otherwise, a random effect model (REM) was used. A funnel plot was performed to look for evidence of publication bias; the funnel plot should be asymmetric when there is publication bias and symmetric in the case of no publication bias. Additionally, the publication bias was quantitatively estimated by Begg’s and Egger’s tests.
RESULTS
Study characteristics
Figure 1 summarizes the selection process of eligible studies. After a thorough literature search, 26 qualified publications[12-37] were included in this meta-analysis according to the inclusion criteria. Among these, 24 were included for the MTHFR C677T polymorphism and GC, and 11 were included for the MTHFR A1298C polymorphism and GC. The characteristics of the included studies, the variant genotypes and allele frequencies are listed in Table 1. Table 2 shows the available data on GCC and NCGC for MTHFR C677T and A1298C in detail. Additionally, data on intestinal and diffuse subtype GC for C677T were accessible in four studies (Table 3). According to the size of the heterogeneity, FEM or REM was adopted to analyze every comparison (Table 4).
Table 1 Characteristics of eligible studies included in the meta-analysis.
Table 4 Comparisons of MTHFR C677T and A1298C polymorphisms for whole and stratified analysis.
n
Case/control
OR (95%CI)
P
PHeterogeneity
OR (95%CI)
P
PHeterogeneity
OR (95%CI)
P
PHeterogeneity
OR (95%CI)
P
PHeterogeneity
(TT + CT)/CC
T/C
TT/CC
TT/(CT + CC)
C677T
Total
24
6266/8250
1.23 (1.08, 1.40)
0.002
< 0.0001
1.15 (1.06, 1.25)
0.001
0.0004
1.37 (1.15, 1.63)
0.0005
0.0005
1.17 (1.07, 1.28)
0.0008
0.01
Eastern
16
4716/5839
1.26 (1.08, 1.47)
0.003
0.002
1.21 (1.08, 1.34)
0.0005
0.002
1.42 (1.15, 1.76)
0.001
0.005
1.22 (1.09, 1.35)
0.0003
0.03
Western
8
1550/2411
1.20 (0.92, 1.56)
0.180
0.002
1.05 (0.91, 1.21)
0.53
0.05
1.28 (0.91, 1.82)
0.16
0.009
1.05 (0.88, 1.25)
0.55
0.11
Tumor site
Cardia
Total
10
1043/2941
1.09 (0.81, 1.48)
0.560
0.0005
1.16 (0.95, 1.41)
0.14
0.002
1.28 (0.85, 1.95)
0.24
0.003
1.38 (1.15, 1.67)
0.0006
0.05
Eastern
7
854/2416
1.16 (0.89, 1.52)
0.280
0.05
1.24 (1.04, 1.48)
0.02
0.06
1.57(1.23, 2.00)
0.0003
0.16
1.53 (1.25, 1.87)
< 0.0001
0.31
Western
3
189/525
1.09 (0.38, 3.12)
0.870
0.001
1.00 (0.52, 1.91)
1.00
0.004
0.78 (0.15, 4.16)
0.77
0.003
0.73 (0.27, 1.99)
0.54
0.07
Non-cardia
Total
8
1008/1794
1.38 (1.18, 1.63)
< 0.0001
0.42
1.24 (1.10, 1.40)
0.0003
0.42
1.44 (1.09, 1.91)
0.01
0.31
1.19 (0.93, 1.52)
0.16
0.61
Eastern
5
600/1269
1.35 (1.10, 1.66)
0.004
0.99
1.21 (1.04, 1.41)
0.01
0.87
1.30 (0.87, 1.95)
0.20
0.48
1.10 (0.79, 1.55)
0.57
0.44
Western
3
408/525
1.41 (0.83, 2.38)
0.400
0.03
1.26 (0.91, 1.76)
0.16
0.06
1.55 (0.86, 2.78)
0.14
0.12
1.29 (0.91, 1.83)
0.16
0.53
Lauren’s classification
Intestinal
Total
4
374/1504
1.46 (0.86, 2.47)
0.160
0.05
1.33 (0.97, 1.84)
0.08
0.10
1.88 (1.22, 2.89)
0.004
0.19
1.45 (1.07, 1.95)
0.02
0.76
Eastern
1
142/780
1.25 (0.87,1.87)
0.230
NA
1.25 (0.95, 1.64)
0.12
NA
1.71 (0.90, 3.26)
0.10
NA
1.60 (0.86, 2.97)
0.14
NA
Western
3
232/724
1.61 (0.60,4.29)
0.340
0.03
1.37 (0.74, 2.52)
0.32
0.04
2.01 (1.13, 3.59)
0.02
0.07
1.41 (1.00, 1.98)
0.05
0.58
Diffuse
Total
4
340/1504
1.31 (0.66,2.58)
0.440
0.03
1.19 (0.78, 1.82)
0.42
0.06
1.46 (0.66, 3.21)
0.35
0.13
0.94 (0.56, 1.58)
0.82
0.09
Eastern
1
80/780
1.24 (0.78,1.96)
0.360
NA
1.21 (0.85, 1.73)
0.29
NA
1.51 (0.64, 3.57)
0.34
NA
1.40 (0.61, 3.20)
0.80
NA
Western
3
260/724
1.33 (0.35,5.01)
0.670
0.008
1.14 (0.50, 2.60)
0.76
0.02
1.31 (0.29, 5.83)
0.72
0.04
0.85 (0.46, 1.55)
0.59
0.1
A1298C
(CC + AC)/AA
C/A
CC/AA
CC/(AC + AA)
Total
11
2007/3679
0.98 (0.79, 1.21)
0.840
0.008
0.97 (0.83, 1.14)
0.73
0.03
0.95 (0.71, 1.28)
0.76
0.60
0.95 (0.72, 1.27)
0.75
0.78
Eastern
7
1015/1452
0.96 (0.72, 1.29)
0.790
0.02
0.93 (0.73, 1.19)
0.56
0.04
0.44 (0.21, 0.93)
0.03
0.84
0.46 (0.22, 0.96)
0.04
0
Western
4
702/1408
1.00 (0.71, 1.41)
0.990
0.04
1.07 (0.93, 1.23)
0.36
0.15
1.13 (0.82, 1.57)
0.46
0.69
1.11 (0.81, 1.51)
0.53
0.98
Tumor site
Cardia
Total
2
111/267
0.80 (0.37, 1.74)
0.240
0.13
0.83 (0.41, 1.69)
0.61
0.10
0.76 (0.21, 2.83)
0.69
0.28
0.80 (0.22, 2.93)
0.73
0.36
Eastern
2
111/267
0.80 (0.37, 1.74)
0.240
0.13
0.83 (0.41, 1.69)
0.61
0.10
0.76 (0.21, 2.83)
0.69
0.28
0.80 (0.22, 2.93)
0.73
0.36
Western
0
0
NA
NA
NA
NA
Non-cardia
Total
3
236/301
0.98 (0.69, 1.41)
0.930
0.59
0.93 (0.68, 1.26)
0.62
0.69
0.45 (0.15, 1.40)
0.17
0.86
0.46 (0.15, 1.40)
0.17
0.82
Eastern
3
236/301
0.98 (0.69, 1.41)
0.930
0.59
0.93 (0.68, 1.26)
0.62
0.69
0.45 (0.15, 1.40)
0.17
0.86
0.46 (0.15, 1.40)
0.17
0.82
Western
0
0
NA
NA
NA
NA
Overall analysis
MTHFR C677T polymorphism and GC: Table 4 lists the main results of this meta-analysis. A total of 6266 cases and 8250 controls were identified for analysis of the association between the MTHFR C677T polymorphism and GC. The overall results showed that there was a significant association between C677T and GC [TT + CT vs CC: OR = 1.23 (1.08, 1.40), P = 0.002], and a T allele was associated with a 15.0% increased risk of GC compared to a C allele [T vs C: OR = 1.15 (1.06, 1.25), P = 0.001]. Similar results were obtained in the analysis for the additive model [TT vs CC: OR = 1.37 (1.15, 1.63), P = 0.0005] and the recessive model [TT vs CT + CC: OR = 1.17 (1.07, 1.28), P = 0.0008].
MTHFR A1298C polymorphism and GC: As shown in Table 4, 11 studies including a total of 2007 cases and 3679 controls were performed to analyze the relationship between the MTHFR A1298C polymorphism and GC. The risk for GC conferred by the MTHFR A1298C polymorphism did not reach significance under the four genetic models (P > 0.05).
Subgroup analysis
When stratifying the data by ethnicity, stronger significance between the MTHFR C677T polymorphism and GC was shown when restricted to eastern populations [TT + CT vs CC: OR = 1.26 (1.08, 1.47), P = 0.003; T vs C: OR = 1.21 (1.08, 1.34), P = 0.0005; TT vs CC: OR = 1.42 (1.15, 1.76), P = 0.001; TT vs CT + CC: OR = 1.22 (1.09, 1.35), P = 0.0003], although the result for western populations was not significant (Table 4). With regard to the A1298C polymorphism, the results showed that there was a significant association between the A1298C polymorphism and a decreased risk of GC in eastern populations in the additive and recessive models [CC vs AA: OR = 0.44 (0.21, 0.93), P = 0.03; CC vs AC + AA: OR = 0.46 (0.22, 0.96), P = 0.04] (Table 4).
Stratification analyses were performed to consider tumor sites. The results suggested that the MTHFR C677T polymorphism was significantly associated with an increased GC risk for both GCC [TT vs CT + CC: OR = 1.38 (1.15, 1.67), P = 0.0006] and NCGC [TT + CT vs CC: OR = 1.38 (1.18, 1.63), P < 0.0001; T vs C: OR = 1.24 (1.10, 1.40), P = 0.0003; TT vs CC: OR = 1.44 (1.09, 1.91), P = 0.01] in the whole population. When further analyzed by ethnicity, similar positive results were found only in eastern but not in western populations. We also obtained no significant results for the association between A1298C and both GCC and NCGC (Table 4).
In view of the Lauren classification, we divided the studies into two subgroups. The results showed that the MTHFR C677T polymorphism was significantly associated with an increased risk for intestinal-type GC [TT vs CC: OR = 1.88 (1.22, 2.89), P = 0.004; TT vs CT + CC: OR = 1.45 (1.07, 1.95), P = 0.02] in the whole population. When further analyzed by ethnicity, similar positive results were found only in western populations but not in eastern populations. No significant relationship was found between the MTHFR C677T polymorphism and diffuse-type GC (Table 4).
Relationships between GCC and NCGC, and intestinal-type and diffuse-type GC
When comparing GCC with NCGC, no significant results were observed in any of the four models for C677T or A1298C (Table 5), and ORs of 1.71 (95%CI: 1.13-2.59, P = 0.01) and 1.60 (95%CI: 1.09-2.35, P = 0.02) were found in the TT vs CC model in western populations and total populations, respectively, when comparing intestinal-type with diffuse-type GC for C677T. None of the other models produced significant results for eastern, western or overall populations (Table 5).
Table 5 Comparisons of MTHFR C677T and A1298C polymorphisms for gastric cardia and non-cardia cancers, intestinal-type and diffuse-type gastric cancers.
n
Case/control
OR (95%CI)
P
PHeterogeneity
OR (95%CI)
P
PHeterogeneity
OR (95%CI)
P
PHeterogeneity
OR (95%CI)
P
PHeterogeneity
C677T
(TT + CT)/CC
T/C
TT/CC
TT/(CT + CC)
Cardia and non-cardia
Total
7
607/970
0.74 (0.51, 1.08)
0.12
0.01
0.80 (0.59, 1.09)
0.2
0.002
0.82 (0.49, 1.38)
0.46
0.01
0.71 (0.36, 1.39)
0.31
0.06
Eastern
4
418/562
0.76 (0.47, 1.21)
0.24
0.04
0.85 (0.56, 1.27)
0.4
0.01
1.04 (0.52, 2.06)
0.91
0.05
0.89 (0.39, 2.03)
0.78
0.10
Western
3
189/408
0.75 (0.35, 1.61)
0.46
0.04
0.73 (0.45, 1.20)
0.2
0.05
0.59 (0.35, 1.00)
0.05
0.08
0.52 (0.17, 1.59)
0.25
0.26
Intestinal-type and diffuse-type
Total
4
374/340
1.09 (0.74, 1.62)
0.67
0.76
1.10 (0.84, 1.45)
0.5
0.78
1.60 (1.09, 2.35)
0.02
0.87
1.24 (0.68, 2.27)
0.48
0.50
Eastern
1
142/80
1.01 (0.58, 1.74)
0.98
NA
1.03 (0.68, 1.57)
0.9
NA
1.14 (0.44, 2.95)
0.79
NA
1.13 (0.42, 3.04)
0.81
NA
Western
3
232/260
1.19 (0.68, 2.09)
0.55
0.54
1.16 (0.81, 1.66)
0.4
0.57
1.71 (1.13, 2.59)
0.01
0.64
1.32 (0.62, 2.80)
0.48
0.41
A1298C
(CC + AC)/AA
C/A
CC/AA
CC/(AC + AA)
Cardia and non-cardia
Total
2
111/198
0.83 (0.26, 2.64)
0.75
0.03
0.90 (0.34, 2.34)
0.8
0.03
1.87 (0.39, 9.03)
0.44
0.59
1.85 (0.39, 8.69)
0.43
0.75
Eastern
2
111/199
0.83 (0.26, 2.64)
0.75
0.03
0.90 (0.34, 2.34)
0.8
0.03
1.87 (0.39, 9.03)
0.44
0.59
1.85 (0.39, 8.69)
0.43
0.75
Western
0
0
NA
NA
NA
NA
Sensitivity analysis and publication bias evaluation
A sensitivity analysis was performed by excluding one study each time to reflect the influence of the individual data set on the ORs; the analysis did not alter the pattern of the results (data not shown), which confirmed the stability of the above results. The funnel plot (data not shown) provided no evidence of publication bias. Consistent results were drawn from Begg’s and Egger’s tests.
DISCUSSION
Regarding the MTHFR C677T and A1298C polymorphisms and their association with GC, definite conclusions cannot be drawn. Therefore, we performed a meta-analysis to estimate the relationships between the two SNPs in the MTHFR gene and the risk of GC.
In the present meta-analysis, the overall analysis suggested that MTHFR 677TT and CT genotype carriers had a higher risk of developing GC; in addition, an elevated risk of GC was also found among the MTHFR 677T allele carriers. It is well known that individuals who are MTHFR 677T carriers have reduced MTHFR activity[10], and the low enzyme activity of MTHFR C677T variant genotypes is associated with DNA hypomethylation, which may induce genomic instability and thereby affect the expression of oncogenes or tumor suppressor genes, leading to the development of malignancies[45,46]. No significant association was found between the MTHFR A1298C polymorphism and overall GC risk; a possible explanation for which could be that the reduction of MTHFR functional activity caused by the A1298C mutation is significantly less than that caused by the C677T mutation[9].
In subgroup analyses stratified by the ethnicity, gastric tumor site and Lauren classification, we found that the MTHFR C677T polymorphism was associated with susceptibility to both GCC and NCGC in eastern populations compared with controls. No positive association was found between the MTHFR C677T polymorphism and the risk of intestinal or diffuse types of GC compared with controls. With regard to the A1298C polymorphism, we found that the CC genotype conferred protection against GC in eastern but not in Western populations; however, the inconsistent results among Western and Eastern populations are difficult to explain. Moreover, irrespective of comparison with controls or diffuse-type GC, a positive association was found that the C677TT polymorphism increased the risk of intestinal-type GC in the whole population and in the western population. No significant difference was found between GCC and NCGC. Because a small sample size was included, this conclusion remains to be confirmed. To the best of our knowledge, the distribution of the MTHFR polymorphism differs among various ethnic populations[47], which may have led to the different results for eastern and western populations.
Although several related meta-analyses have been published previously[38-44], our current research still has some advantages. First, because it involved 26 studies conforming to HWE and provided 6390/8515 cases/controls, our meta-analysis included a larger number of studies than the previous studies, and the results are more reliable. Second, our study is the first to include stratification according to tumor site and Lauren classification.
There was a certain degree of heterogeneity among the studies assessed here, which may be attributed to design quality, sample size, noncomparable measures of genotyping, and variation of the covariate. To clarify the sources of heterogeneity, we conducted a sensitivity analysis, and this analysis confirmed the stability of the null association between MTHFR polymorphisms and GC after excluding any one study at a time.
No significant publication bias was found herein given the symmetry shown in the funnel plots, and consistent results were drawn from Begg’s and Egger’s tests (data not shown). Nevertheless, unpublished data from conference abstracts and dissertations and unpublished pharmaceutical company data were not extracted, which could introduce a distinct possibility of publication bias. Moreover, we followed the inclusion and exclusion criteria strictly to reduce selection bias. In addition, the test of HWE for the distribution of the genotypes in the control groups suggested that there were no individuals with significantly aberrant genetic backgrounds among the participants.
Nevertheless, this meta-analysis had several limitations that may have affected the conclusions. First, we selected only the MTHFR C677T and A1298C polymorphisms because these were the most extensively studied polymorphisms, although several other SNPs in the MTHFR gene have been identified. Meta-analyses that investigate the association of other polymorphisms in the MTHFR gene with GC should be performed in the future. Second, study design, small sample size and environmental factors may have affected the results; many studies did not use an appropriate design or neglected to consider important environmental factors. Third, the results drawn from subgroup analyses might be limited because of the small sample size. Moreover, it was difficult to obtain full papers published in various languages; we included studies published only in English and Chinese.
In summary, data from our meta-analysis support that the MTHFR C677T polymorphism increases the risk of developing GC in the general population, as well as the risk of GCC and NCGC in eastern populations and intestinal-type GC in western populations. The A1298C polymorphism may be a protective factor against GC in eastern populations. GC is a disease resulting from complex interactions between genes and the environment. Therefore, further well-designed studies with larger sample sizes should be performed to assess other genetic and environmental factors in the development of GC.
COMMENTS
Background
Currently, the incidence of gastric cancer (GC) has decreased worldwide, but it remains the fourth most common cancer diagnosis in men, and the fifth in women, and the second leading cause of cancer-related death. Methylenetetrahydrofolate reductase (MTHFR) encodes a 77-kDa protein that plays a key role in DNA methylation. Many studies have explored the association between MTHFR polymorphisms and GC risk, but the results remain either controversial or inconclusive. Consequently, the authors performed a meta-analysis to clarify the role of MTHFR polymorphisms in GC susceptibility among the eligible studies.
Research frontiers
Until now, many studies have reported associations of MTHFR polymorphisms with susceptibility to GC; however, the results have been inconsistent and inconclusive.
Innovations and breakthroughs
This meta-analysis indicates that the MTHFR C677T polymorphism is a risk factor in GC and that the A1298C polymorphism may be a protective factor against GC in eastern populations. Moreover, this study is the first to include stratification according to tumor site and Lauren classification.
Applications
This meta-analysis showed that the C677T and A1298C polymorphisms of the MTHFR gene could alter susceptibility to GC. The findings may provide valuable information about the etiology of GC for both researchers and clinicians.
Terminology
MTHFR encodes a 77-kDa protein that plays a key role in folate metabolism by irreversibly catalyzing the reduction of 5, 10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the predominant circulatory form of folate, which serves as both a cofactor and substrate for the regeneration of methionine. The latter leads to the production of S-adenosylmethionine (SAM), the universal methyl donor in humans for DNA methylation. Reduced enzyme activity may result in lower levels of SAM and an increased risk of cancer, including GC, as a consequence of gene hypomethylation.
Peer review
This meta-analysis was a well-written and well-conducted study that evaluated the association of MTHFR polymorphisms with susceptibility to gastric cancer. It had a large sample size, which allowed consistent conclusions in relation to the general population. Additionally, this study is the first to include stratification according to gastric cancer location and histological subtype. It is important to review these relevant reports systematically.
Footnotes
P- Reviewer: Jonaitis L, Santos JS, Zhang SN S- Editor: Gou SX L- Editor: Kerr C E- Editor: Zhang DN
Rozen R. Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahydrofolate reductase (MTHFR).Thromb Haemost. 1997;78:523-526.
[PubMed] [DOI][Cited in This Article: ]
Stern LL, Mason JB, Selhub J, Choi SW. Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene.Cancer Epidemiol Biomarkers Prev. 2000;9:849-853.
[PubMed] [DOI][Cited in This Article: ]
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase.Nat Genet. 1995;10:111-113.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 3965][Cited by in F6Publishing: 3947][Article Influence: 131.6][Reference Citation Analysis (0)]
Guo W, Chen P, Zheng LH, Li S. Association between methylenetetrahydrofolate reductase gene polymorphisms (C677T and G1793A) and risk of gastric cancer.Shijie Huaren Xiaohua Zazhi. 2012;20:690-693.
[PubMed] [DOI][Cited in This Article: ]
Saberi S, Zendehdel K, Jahangiri S, Talebkhan Y, Abdirad A, Mohajerani N, Bababeik M, Karami N, Esmaili M, Oghalaie A. Impact of methylenetetrahydrofolate reductase C677T polymorphism on the risk of gastric cancer and its interaction with Helicobacter pylori infection.Iran Biomed J. 2012;16:179-184.
[PubMed] [DOI][Cited in This Article: ]
Yang XX, Li F, Yi JP, Li X, Sun JZ, Hu NY. Methylenetetrahydrofolate reductase C677T polymorphism in patients with gastric, colorectal and lung cancer.Guangdong Yixue. 2010;31:2375-2378.
[PubMed] [DOI][Cited in This Article: ]
Galván-Portillo MV, Cantoral A, Oñate-Ocaña LF, Chen J, Herrera-Goepfert R, Torres-Sanchez L, Hernandez-Ramirez RU, Palma-Coca O, López-Carrillo L. Gastric cancer in relation to the intake of nutrients involved in one-carbon metabolism among MTHFR 677 TT carriers.Eur J Nutr. 2009;48:269-276.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 27][Cited by in F6Publishing: 27][Article Influence: 1.7][Reference Citation Analysis (0)]
Vollset SE, Igland J, Jenab M, Fredriksen A, Meyer K, Eussen S, Gjessing HK, Ueland PM, Pera G, Sala N. The association of gastric cancer risk with plasma folate, cobalamin, and methylenetetrahydrofolate reductase polymorphisms in the European Prospective Investigation into Cancer and Nutrition.Cancer Epidemiol Biomarkers Prev. 2007;16:2416-2424.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 47][Cited by in F6Publishing: 47][Article Influence: 2.8][Reference Citation Analysis (0)]
Boccia S, Gianfagna F, Persiani R, La Greca A, Arzani D, Rausei S, D’ugo D, Magistrelli P, Villari P, Van Duijn CM. Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and susceptibility to gastric adenocarcinoma in an Italian population.Biomarkers. 2007;12:635-644.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 24][Cited by in F6Publishing: 28][Article Influence: 1.6][Reference Citation Analysis (0)]
Fu G, Yang FY, Shen XB, PU YP, Zhang J. Relationship between the Methylenetetrahydrofolate Reductase A1298C Genetic Polymorphisms and Susceptibility to Gastric Cancer.J Environ Occup Med. 2007;24:32-35.
[PubMed] [DOI][Cited in This Article: ]
Graziano F, Kawakami K, Ruzzo A, Watanabe G, Santini D, Pizzagalli F, Bisonni R, Mari D, Floriani I, Catalano V. Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk Italian population.Int J Cancer. 2006;118:628-632.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 49][Cited by in F6Publishing: 52][Article Influence: 2.7][Reference Citation Analysis (0)]
Li S, Cai MJ, Hou P, He NY. Single nucleotide polymorphisms (C677T and A1298C) in methylenetetrahy 2 drofolate reductase gene and suscepcipility to gastric carcinoma.Dongnan Daxue Xuebao. 2006;25:321-324.
[PubMed] [DOI][Cited in This Article: ]
Weng YR, Sun DF, Fang JY, Gu WQ, Zhu HY. Folate levels in mucosal tissue but not methylenetetrahydrofolate reductase polymorphisms are associated with gastric carcinogenesis.World J Gastroenterol. 2006;12:7591-7597.
[PubMed] [DOI][Cited in This Article: ]
Kim JK, Kim S, Han JH, Kim HJ, Chong SY, Hong SP, Hwang SG, Ahn JY, Cha KY, Oh D. Polymorphisms of 5,10-methylenetetrahydrofolate reductase and risk of stomach cancer in a Korean population.Anticancer Res. 2005;25:2249-2252.
[PubMed] [DOI][Cited in This Article: ]
Si PR, Fang DC, Zhang H, Yang LQ, Luo YH, Liao HY. The relationship between metbylenetetrahydrofolate reductase gene polymorphism and microsatellite instability in gastric cancer.Zhonghua Liuxingbing Zazhi. 2005;26:794-799.
[PubMed] [DOI][Cited in This Article: ]
Bi JP, Cai L, Zheng ZL. Study on C667T gene polymorphism and susceptibility to gastric cancer.Zhongguo Gonggong Weisheng. 2005;21:661-663.
[PubMed] [DOI][Cited in This Article: ]
Wang LD, Guo RF, Fan ZM, He X, Gao SS, Guo HQ, Matsuo K, Yin LM, Li JL. Association of methylenetetrahydrofolate reductase and thymidylate synthase promoter polymorphisms with genetic susceptibility to esophageal and cardia cancer in a Chinese high-risk population.Dis Esophagus. 2005;18:177-184.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 40][Cited by in F6Publishing: 39][Article Influence: 2.0][Reference Citation Analysis (0)]
Stolzenberg-Solomon RZ, Qiao YL, Abnet CC, Ratnasinghe DL, Dawsey SM, Dong ZW, Taylor PR, Mark SD. Esophageal and gastric cardia cancer risk and folate- and vitamin B(12)-related polymorphisms in Linxian, China.Cancer Epidemiol Biomarkers Prev. 2003;12:1222-1226.
[PubMed] [DOI][Cited in This Article: ]
Miao X, Xing D, Tan W, Qi J, Lu W, Lin D. Susceptibility to gastric cardia adenocarcinoma and genetic polymorphisms in methylenetetrahydrofolate reductase in an at-risk Chinese population.Cancer Epidemiol Biomarkers Prev. 2002;11:1454-1458.
[PubMed] [DOI][Cited in This Article: ]
Gao CM, Wu JZ, Ding JH, Liu YT, Zang Y, Li SP, Su P, Hu X, Xu TL. Polymorphisms of methylenetetrahydrofolate reductase C677T and the risk of stomach cancer.Zhonghua Liuxingbing Zazhi. 2002;23:289-292.
[PubMed] [DOI][Cited in This Article: ]
Shen H, Xu Y, Zheng Y, Qian Y, Yu R, Qin Y, Wang X, Spitz MR, Wei Q. Polymorphisms of 5,10-methylenetetrahydrofolate reductase and risk of gastric cancer in a Chinese population: a case-control study.Int J Cancer. 2001;95:332-336.
[PubMed] [DOI][Cited in This Article: ][Cited by in F6Publishing: 1][Reference Citation Analysis (0)]
Boccia S, Hung R, Ricciardi G, Gianfagna F, Ebert MP, Fang JY, Gao CM, Götze T, Graziano F, Lacasaña-Navarro M. Meta- and pooled analyses of the methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer risk: a huge-GSEC review.Am J Epidemiol. 2008;167:505-516.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 79][Cited by in F6Publishing: 89][Article Influence: 5.2][Reference Citation Analysis (0)]
Zacho J, Yazdanyar S, Bojesen SE, Tybjærg-Hansen A, Nordestgaard BG. Hyperhomocysteinemia, methylenetetrahydrofolate reductase c.677C > T polymorphism and risk of cancer: cross-sectional and prospective studies and meta-analyses of 75,000 cases and 93,000 controls.Int J Cancer. 2011;128:644-652.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 43][Cited by in F6Publishing: 48][Article Influence: 3.4][Reference Citation Analysis (0)]